• 1
    Cella M, Knibbe C, Danhof M, Della Pasqua O. What is the right dose for children? Br J Clin Pharmacol 2010; 70: 597603.
  • 2
    Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 2006; 45: 683704.
  • 3
    Knibbe CA, Danhof M. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm 2011; 415: 914.
  • 4
    Kleiber M. Energy metabolism. Annu Rev Physiol 1956; 18: 3552.
  • 5
    Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303332.
  • 6
    Edginton AN, Willmann S. Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paed Perinat Drug Ther 2006; 7: 146153.
  • 7
    Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006; 61: 545557.
  • 8
    Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel D, Danhof M, Knibbe CA. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res 2012; 29: 15701581.
  • 9
    Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, Shaw PJ, Nath CE, Hempel G, Zwaveling J, Danhof M, Knibbe CA. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet 2012; 51: 331345.
  • 10
    Habtemariam B, Sallas W, Sunkara G, Kern S, Jarugula V, Pillai G. Population pharmacokinetics of valsartan in pediatrics. Drug Metab Pharmacokinet 2009; 24: 145152.
  • 11
    Allegaert K, de Hoon J, Verbesselt R, Naulaers G, Murat I. Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatr Anaesth 2007; 17: 10281034.
  • 12
    Standing JF, Howard RF, Johnson A, Savage I, Wong IC. Population pharmacokinetics of oral diclofenac for acute pain in children. Br J Clin Pharmacol 2008; 66: 846853.
  • 13
    El-Tahtawy A, Kokki H, Reidenberg BE. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. J Clin Pharmacol 2006; 46: 433442.
  • 14
    Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 2009; 50: 11501157.
  • 15
    Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, Simons SH, van Lingen RA, Jacqz-Aigrain EM, Danhof M, Tibboel D. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009; 48: 371385.
  • 16
    CDER/FDA. General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products – Draft Guidance. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research, 1998.
  • 17
    Allegaert K, Peeters MY, Verbesselt R, Tibboel D, Naulaers G, de Hoon JN, Knibbe CA. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth 2007; 99: 864870.
  • 18
    Peeters MY, Prins SA, Knibbe CA, DeJongh J, van Schaik RH, van Dijk M, van der Heiden IP, Tibboel D, Danhof M. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006; 104: 466474.
  • 19
    Murat I, Billard V, Vernois J, Zaouter M, Marsol P, Souron R, Farinotti R. Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. Anesthesiology 1996; 84: 526532.
  • 20
    Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, Mandema JW, Shafer SL. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994; 80: 104122.
  • 21
    Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Cella M, Tibboel D, Danhof M, Knibbe CA. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010; 49: 269275.
  • 22
    Knibbe CA, Voortman HJ, Aarts LP, Kuks PF, Lange R, Langemeijer HJ, Danhof M. Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs. propofol 1% SAZN and Diprivan-10 after bolus injection. Br J Clin Pharmacol 1999; 47: 653660.
  • 23
    Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, Youngs EJ. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998; 88: 11701182.
  • 24
    Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res 2011; 28: 797811.
  • 25
    Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 1720.
  • 26
    Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg 1987; 66: 12561263.
  • 27
    Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991; 67: 4148.
  • 28
    Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 2000; 92: 727738.
  • 29
    Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, Knibbe CA, Vinks AA. Propofol clearance in morbidly obese children and adolescents: influence of age and body size. Clin Pharmacokinet 2012; 51: 543551.
  • 30
    McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 2012; 51: 319330.
  • 31
    Knibbe CA, Zuideveld KP, Aarts LP, Kuks PF, Danhof M. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol 2005; 59: 705711.
  • 32
    Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 2003; 43: 133140.
  • 33
    Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol 2003; 43: 698710.
  • 34
    Bouazza N, Urien S, Hirt D, Frange P, Rey E, Benaboud S, Foissac F, Blanche S, Treluyer JM. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. J Acquir Immune Defic Syndr 2011; 58: 283288.
  • 35
    Bjorkman S. Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods? Clin Pharmacokinet 2006; 45: 111.
  • 36
    Mahmood I. Evaluation of sigmoidal maturation and allometric models: prediction of propofol clearance in neonates and infants. Am J Ther 2013; 20: 2128.
  • 37
    Paci A, Vassal G, Moshous D, Dalle JH, Bleyzac N, Neven B, Galambrun C, Kemmel V, Abdi ZD, Broutin S, Petain A, Nguyen L. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit 2012; 34: 198208.
  • 38
    CDER/FDA. Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2003.
  • 39
    CDER/FDA. Summary minutes of the advisory committee for pharmaceutical science and clinical pharmacology March 14 2012. 2012.
  • 40
    Mahmood I. Prediction of drug clearance in children 3 months and younger: an allometric approach. Drug Metabol Drug Interact 2010; 25: 2534.